Key facts

Active substance
Anti proprotein convertase subtilisin kexin type 9 humanized monoclonal antibody (PF-04950615)
Therapeutic area
Endocrinology, -gynacology-fertility-metabolism
Decision number
PIP number
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
  • Prevention of cardiovascular events in patients with cardiovascular disease or cardiovascular disease risk equivalent
  • Treatment of mixed dyslipidaemia
  • Treatment of elevated cholesterol
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Pfizer Limited

E-mail: pip_enquiries@pfizer.com
Tel. +44 (0)1304 646607

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)


How useful was this page?

Add your rating